<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419718</url>
  </required_header>
  <id_info>
    <org_study_id>NN1998-1562</org_study_id>
    <nct_id>NCT00419718</nct_id>
  </id_info>
  <brief_title>Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes</brief_title>
  <official_title>Effect of Exercise on the Pharmacokinetics and Pharmacodynamics of Inhaled Human Insulin in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted in Europe. This clinical pharmacology trial investigates the effect of
      exercise on the pharmacokinetics and pharmacodynamics of inhaled insulin in subjects with
      type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma insulin profile in the interval</measure>
    <time_frame>From 30-150 min after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma insulin profile in the interval from 120-240 min after trial product administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma insulin profile in the interval from 240-360 min after trial product administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma insulin profile in the interval 0-600 min after trial product administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma insulin concentration</measure>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled human insulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes more than or equal to 12 months

          -  Baseline HbA1c less than or equal to 11%

          -  Body mass index (BMI) less than or equal to 29 kg/m2

          -  Normal lung volumes

          -  Treatment with intensified insulin therapy for at least 3 months

        Exclusion Criteria:

          -  Any present or history of pulmonary disease

          -  Any findings from the cardiopulmonary exercise test compromising safety of moderate
             exercise

          -  Impaired hepatic or renal function

          -  Cardiac problems

          -  Uncontrolled hypertension

          -  Current proliferative retinopathy or maculopathy

          -  Treatment with drugs, which may interfere with insulin action, glucose metabolism or
             recovery from hypoglycaemia (judged by investigator)

          -  Current smoking or smoking within the last 6 months

          -  Blood donation (more than 500 mL) within the last nine weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Petersen AH, KÃ¶hler G, Korsatko S, Wutte A, Wonisch M, Jeppesen OK, Sparre T, Clauson P, Laursen T, Wollmer P, Pieber TR. The effect of exercise on the absorption of inhaled human insulin via the AERx insulin diabetes management system in people with type 1 diabetes. Diabetes Care. 2007 Oct;30(10):2571-6. Epub 2007 Jul 9.</citation>
    <PMID>17620446</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

